NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
13 Mar 2017

TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction

TiGenix NV today announced top-line one-year results from the CAREMI clinical trial, an exploratory Phase I/II study of AlloCSCs in acute myocardial infarction (AMI).
09 Mar 2017

TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial

TiGenix NV today announced week 104 data from the Cx601 ADMIRE-CD study, a pivotal Phase III trial for complex perianal fistulas in Crohn’s disease patients. 
07 Mar 2017

TiGenix Receives Positive Feedback from the FDA on Cx601 Global Phase III Trial Protocol

TiGenix NV announced today that it has received positive feedback from the U.S. Food and Drug Administration (FDA) on an improved protocol for its global Phase III trial for the treatment of complex perianal fistulas in Crohn’s disease patients. 
06 Mar 2017

TiGenix Provides Update on Cx601 Marketing Authorization Application procedure in Europe

TiGenix NV announces that it has received the Day 180 List of Outstanding Issues (LoOI) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and expects to receive a Marketing Authorization decision for Cx601 in 2017. 
22 Feb 2017

Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102

Minoryx Therapeutics, today announces that its lead compound MIN-102 has been granted Orphan Drug Designation by the US Food and Drug Administration body (FDA).
17 Feb 2017

Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601

Takeda Pharmaceutical Company today announced new data from the Phase 3 ADMIRE-CD clinical trial.
08 Feb 2017

Dr Claude Nicaise joins Minoryx Therapeutics as independent board member

Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces that Dr Claude Nicaise has joined its board of directors as an independent member.
08 Feb 2017

Prexton Therapeutics Series B financing round raises EUR 29 million (USD 31 million) to advance its novel Parkinson’s therapeutic

Prexton Therapeutics (Prexton), today announces the closing of a Series B financing round of EUR 29 million (USD 31 million).
Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma<
06 Feb 2017

Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma

Landmark clinical trial has launched for rare disease with no approved targeted therapy.
31 Jan 2017

TiGenix Enrolls First Patient in Phase Ib/IIa Clinical Trial of Cx611 in Severe Sepsis

TiGenix NV today announced that the first patient has been enrolled and treated in its Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка